BioCryst Pharmaceuticals (BCRX) News Today $7.57 +0.18 (+2.44%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Wellington Management Group LLP Invests $819,000 in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Wellington Management Group LLP bought a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 107,820 shares of the biotechnology company's stock, valDecember 20 at 3:39 AM | marketbeat.comXTX Topco Ltd Has $241,000 Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)XTX Topco Ltd lowered its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 79.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,670 shares of the biotechnology company's sDecember 19 at 3:52 AM | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by State Street CorpState Street Corp reduced its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 5.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,849,588 shares of the biotechnology company's stock after sellDecember 18 at 3:35 AM | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down - What's Next?BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down - What's Next?December 17, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Verition Fund Management LLCVerition Fund Management LLC lowered its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 72.2% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 39,520 shares of the biotechnology company's stock after selling 102,839 sharesDecember 15, 2024 | marketbeat.comBioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A BuyDecember 9, 2024 | seekingalpha.comTwo Sigma Advisers LP Increases Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Two Sigma Advisers LP raised its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 13.6% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,181,012 shares of the biotechnology company's stock aftDecember 9, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Increases Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)The Manufacturers Life Insurance Company grew its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 40.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 299December 9, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys 102,860 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Charles Schwab Investment Management Inc. grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 5.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,887,994 shares of the bioteDecember 9, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $2.79 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Jacobs Levy Equity Management Inc. lowered its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 50.3% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 367,514 shares of the biotechnology company's stock after selling 372,085December 8, 2024 | marketbeat.comBioCryst price target raised to $18 from $16 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.comBNP Paribas Financial Markets Buys 409,938 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)BNP Paribas Financial Markets raised its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 472.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 496,784 shares of the biotechnology compaDecember 5, 2024 | marketbeat.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 4, 2024 | globenewswire.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from AnalystsShares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recDecember 4, 2024 | marketbeat.comCinctive Capital Management LP Makes New $2.08 Million Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Cinctive Capital Management LP acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 273,959 shares of the biotechnology company's stock, valued at approxiDecember 3, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is Caligan Partners LP's 7th Largest PositionCaligan Partners LP lowered its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 43.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,583,585 shares of the biotechnology company's stockDecember 1, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Position Lifted by Fisher Asset Management LLCFisher Asset Management LLC boosted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 16.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,338,062 shares of the biotNovember 28, 2024 | marketbeat.comAlgert Global LLC Raises Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Algert Global LLC raised its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 46.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 516,209 shares of the biotechnology company's stock after purchasing an additNovember 26, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Lowers Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Connor Clark & Lunn Investment Management Ltd. cut its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 12.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 682,324 shares of the biotecNovember 24, 2024 | marketbeat.comPrincipal Financial Group Inc. Buys 375,890 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Principal Financial Group Inc. boosted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 1,058.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 411,414 shares ofNovember 23, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Holdings Increased by Counterweight Ventures LLCCounterweight Ventures LLC grew its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 591.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 93,384 shares of the biotechnologNovember 19, 2024 | marketbeat.comBioCryst launches Orladeyo in irelandNovember 18, 2024 | markets.businessinsider.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Large Drop in Short InterestBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the recipient of a significant drop in short interest in October. As of October 31st, there was short interest totalling 20,830,000 shares, a drop of 7.5% from the October 15th total of 22,530,000 shares. Based on an average daily volume of 1,950,000 shares, the days-to-cover ratio is currently 10.7 days.November 18, 2024 | marketbeat.comBioCryst Launches ORLADEYO® (berotralstat) in IrelandNovember 18, 2024 | globenewswire.comBioCryst (BCRX) Receives a Buy from Bank of America SecuritiesNovember 14, 2024 | markets.businessinsider.comGSA Capital Partners LLP Sells 78,250 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)GSA Capital Partners LLP lowered its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 21.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 285,588 shares of the biotechnology company's stNovember 12, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of "Moderate Buy" by BrokeragesShares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have assignNovember 9, 2024 | marketbeat.comVanguard Group Inc's Strategic Acquisition in BioCryst Pharmaceuticals IncNovember 7, 2024 | gurufocus.comWhat is HC Wainwright's Forecast for BCRX Q4 Earnings?BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities researchers at HC Wainwright lifted their Q4 2024 earnings estimates for BioCryst Pharmaceuticals in a research note issued to investors on Tuesday, November 5th. HC Wainwright analyst A. Fein now anticipates that the biotechnoNovember 7, 2024 | marketbeat.comDrugmaker eyes billion-dollar pillNovember 7, 2024 | bizjournals.comEvercore ISI Reaffirms Their Buy Rating on BioCryst (BCRX)November 7, 2024 | markets.businessinsider.comBioCryst to Present at Upcoming Investor ConferencesNovember 6, 2024 | globenewswire.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Earnings Results, Meets EstimatesBioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. The firm's revenue was up 35.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.19) earnings per share.November 5, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | msn.comBioCryst Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 5, 2024 | finance.yahoo.comBarclays Keeps Their Hold Rating on BioCryst (BCRX)November 5, 2024 | markets.businessinsider.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Earns Outperform Rating from Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday.November 5, 2024 | marketbeat.comBarclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) StockBarclays upped their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research note on Tuesday.November 5, 2024 | marketbeat.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 5, 2024 | globenewswire.comBioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ...November 5, 2024 | finance.yahoo.comBioCryst Pharmaceuticals Reports Strong Q3 2024 ResultsNovember 5, 2024 | markets.businessinsider.comBioCryst: Strong Growth Potential and Strategic Positioning Underpin Buy RecommendationNovember 5, 2024 | markets.businessinsider.comBioCryst Announces Strong Q3 2024 Revenue GrowthNovember 4, 2024 | markets.businessinsider.comBioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call TranscriptNovember 4, 2024 | msn.comBioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call TranscriptNovember 4, 2024 | seekingalpha.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down - Time to Sell?BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down - What's Next?November 4, 2024 | marketbeat.comBioCryst Pharmaceuticals Q3 2024 Earnings: EPS Loss of $0.07, Revenue Hits $117. ...November 4, 2024 | gurufocus.comBioCryst Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 4, 2024 | seekingalpha.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Rice Hall James & Associates LLCRice Hall James & Associates LLC grew its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,163,743 shares of the biotechnology company's stock afterNovember 1, 2024 | marketbeat.comSemanteon Capital Management LP Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Semanteon Capital Management LP bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 149,576 shares of the biotechnology company's stock, valued at approximately $1October 28, 2024 | marketbeat.com Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address AI breakthrough about to upend industry (Ad)Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing. I urge you to watch it now. BCRX Media Mentions By Week BCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCRX News Sentiment▼1.130.60▲Average Medical News Sentiment BCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCRX Articles This Week▼55▲BCRX Articles Average Week Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IONS News Today ALKS News Today FOLD News Today LGND News Today GERN News Today CLDX News Today MNKD News Today DVAX News Today NVAX News Today MYGN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCRX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCRX Stock Alerts